Silexion Therapeutics Announces $6M Public Offering

Silexion Therapeutics ( (SLXN) ) just unveiled an announcement.

On September 11, 2025, Silexion Therapeutics announced the pricing of a $6.0 million public offering, which included ordinary shares and warrants. The proceeds from this offering are intended to support the company’s pre-clinical and clinical studies and general corporate purposes. The offering, facilitated by H.C. Wainwright & Co., is expected to impact Silexion’s operations by providing necessary capital to advance its research and development efforts in oncology.

The most recent analyst rating on (SLXN) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Spark’s Take on SLXN Stock

According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.

Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.

To see Spark’s full report on SLXN stock, click here.

More about Silexion Therapeutics

Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers, which are among the most common oncogenic gene drivers in human cancers. The company is dedicated to advancing innovative treatments for solid tumor cancers and has conducted a Phase 2a clinical trial showing positive trends with its first-generation product.

Average Trading Volume: 364,034

Technical Sentiment Signal: Sell

Current Market Cap: $3.61M

For a thorough assessment of SLXN stock, go to TipRanks’ Stock Analysis page.